ZA96431B - Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs - Google Patents

Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs

Info

Publication number
ZA96431B
ZA96431B ZA96431A ZA96431A ZA96431B ZA 96431 B ZA96431 B ZA 96431B ZA 96431 A ZA96431 A ZA 96431A ZA 96431 A ZA96431 A ZA 96431A ZA 96431 B ZA96431 B ZA 96431B
Authority
ZA
South Africa
Prior art keywords
carnitine
cylcosporin
immuno
reducing
toxic effects
Prior art date
Application number
ZA96431A
Other languages
English (en)
Inventor
Menooti Calvani
Luigi Mosconi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ZA96431B publication Critical patent/ZA96431B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA96431A 1995-01-20 1996-01-19 Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs ZA96431B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Publications (1)

Publication Number Publication Date
ZA96431B true ZA96431B (en) 1996-08-08

Family

ID=11402949

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96431A ZA96431B (en) 1995-01-20 1996-01-19 Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs

Country Status (13)

Country Link
US (2) US5955424A (xx)
EP (1) EP0722724B1 (xx)
JP (1) JPH08231390A (xx)
KR (1) KR100443730B1 (xx)
AT (1) ATE177946T1 (xx)
CA (1) CA2167456A1 (xx)
DE (1) DE69508551T2 (xx)
DK (1) DK0722724T3 (xx)
ES (1) ES2130509T3 (xx)
GR (1) GR3030545T3 (xx)
IT (1) IT1277147B1 (xx)
TW (1) TW445145B (xx)
ZA (1) ZA96431B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
IT1306179B1 (it) 1999-07-28 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
CA2424823A1 (en) * 2000-10-12 2002-04-18 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
JPH01213258A (ja) * 1988-02-23 1989-08-28 Kyowa Hakko Kogyo Co Ltd カルニチンおよびカルニチンアミドの精製法

Also Published As

Publication number Publication date
EP0722724A1 (en) 1996-07-24
ITRM950037A1 (it) 1996-07-20
GR3030545T3 (en) 1999-10-29
US5955424A (en) 1999-09-21
DK0722724T3 (da) 1999-10-11
IT1277147B1 (it) 1997-11-04
DE69508551D1 (de) 1999-04-29
KR960029314A (ko) 1996-08-17
DE69508551T2 (de) 1999-09-02
ATE177946T1 (de) 1999-04-15
ITRM950037A0 (it) 1995-01-20
TW445145B (en) 2001-07-11
KR100443730B1 (ko) 2004-10-14
US5958941A (en) 1999-09-28
JPH08231390A (ja) 1996-09-10
ES2130509T3 (es) 1999-07-01
CA2167456A1 (en) 1996-07-21
EP0722724B1 (en) 1999-03-24

Similar Documents

Publication Publication Date Title
ZA96431B (en) Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs
HK1040631A1 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues.
CA2279522A1 (en) Biocompatible compounds for pharmaceutical drug delivery systems
MY125662A (en) Pharmaceutical formulations containing darifenacin
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
CA2209001A1 (en) Hydrophobic taxane derivatives
CA2275889A1 (en) Formulation and method for treating neoplasms by inhalation
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
CA2053826A1 (en) Pharmaceutical compositions active in the therapy of neurological affections in aids patients
IL123551A0 (en) Tricyclic erythromycin derivatives
EP0620004A4 (en) MEDICAL COMPOSITION.
TW221441B (xx)
UA29435C2 (uk) Похідні 3бета-алкенілпенаму та їх фармацевтично прийнятні солі
ZA892188B (en) Peptide derivatives
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
GB9420748D0 (en) 1,5 benzodiazepine derivatives
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
CA2184395A1 (en) Effective dosage form for antiepileptic drugs
AU3080692A (en) Slow-release medicament containing a dihydropyridine derivate as a nanosol and its preparation
CA2235942A1 (en) Tricyclic erythromycin derivatives
TH33442A (th) อนุพันธ์ของเตตร้าไฮโดรไอโดรไอโซควิโนลีน